Shelli Avenevoli1, Joel Swendsen2, Jian-Ping He3, Marcy Burstein4, Kathleen Ries Merikangas5. 1. Division of Translational Research, National Institute of Mental Health (NIMH), Bethesda, MD. 2. École Pratique des Hautes Études (EPHE), Centre national de la recherche scientifique (CNRS), University of Bordeaux, France. 3. Genetic Epidemiology Research Branch, Intramural Research Program, NIMH. 4. Extramural Review Branch, Division of Extramural Activities, NIMH. 5. Genetic Epidemiology Research Branch, Intramural Research Program, NIMH. Electronic address: Kathleen.merikangas@nih.gov.
Abstract
OBJECTIVE: To present the 12-month prevalence of DSM-IV major depressive disorder (MDD) and severe MDD; to examine sociodemographic correlates and comorbidity; and to describe impairment and service use. METHOD: Data are from the National Comorbidity Survey-Adolescent Supplement (NCS-A), a nationally representative survey of 10,123 adolescents aged 13 to 18 years that assesses DSM-IV disorders using the Composite International Diagnostic Interview (CIDI) Version 3.0. One parent or surrogate of each participating adolescent was also asked to complete a self-administered questionnaire. RESULTS: Lifetime and 12-month prevalence of MDD were 11.0% and 7.5%, respectively. The corresponding rates of severe MDD were 3.0% and 2.3%. The prevalence of MDD increased significantly across adolescence, with markedly greater increases among females than among males. Most cases of MDD were associated with psychiatric comorbidity and severe role impairment, and a substantial minority reported suicidality. The prevalence of severe MDD was about one-fourth of that of all MDD cases; estimates of impairment and clinical correlates were of 2- to 5-fold greater magnitude for severe versus mild/moderate depression, with markedly higher rates for suicidal thoughts and behaviors. Treatment in any form was received by the majority of adolescents with 12-month DSM-IV MDD (60.4%), but only a minority received treatment that was disorder-specific or from the mental health sector. CONCLUSION: Findings underscore the important public health significance of depression among US adolescents and the urgent need to improve screening and treatment access in this population. Published by Elsevier Inc.
OBJECTIVE: To present the 12-month prevalence of DSM-IV major depressive disorder (MDD) and severe MDD; to examine sociodemographic correlates and comorbidity; and to describe impairment and service use. METHOD: Data are from the National Comorbidity Survey-Adolescent Supplement (NCS-A), a nationally representative survey of 10,123 adolescents aged 13 to 18 years that assesses DSM-IV disorders using the Composite International Diagnostic Interview (CIDI) Version 3.0. One parent or surrogate of each participating adolescent was also asked to complete a self-administered questionnaire. RESULTS: Lifetime and 12-month prevalence of MDD were 11.0% and 7.5%, respectively. The corresponding rates of severe MDD were 3.0% and 2.3%. The prevalence of MDD increased significantly across adolescence, with markedly greater increases among females than among males. Most cases of MDD were associated with psychiatric comorbidity and severe role impairment, and a substantial minority reported suicidality. The prevalence of severe MDD was about one-fourth of that of all MDD cases; estimates of impairment and clinical correlates were of 2- to 5-fold greater magnitude for severe versus mild/moderate depression, with markedly higher rates for suicidal thoughts and behaviors. Treatment in any form was received by the majority of adolescents with 12-month DSM-IV MDD (60.4%), but only a minority received treatment that was disorder-specific or from the mental health sector. CONCLUSION: Findings underscore the important public health significance of depression among US adolescents and the urgent need to improve screening and treatment access in this population. Published by Elsevier Inc.
Entities:
Keywords:
adolescence; depression; epidemiology; service use
Authors: P S Jensen; M Rubio-Stipec; G Canino; H R Bird; M K Dulcan; M E Schwab-Stone; B B Lahey Journal: J Am Acad Child Adolesc Psychiatry Date: 1999-12 Impact factor: 8.829
Authors: Jan Spijker; Ron de Graaf; Rob V Bijl; Aartjan T F Beekman; Johan Ormel; Willem A Nolen Journal: Br J Psychiatry Date: 2002-09 Impact factor: 9.319
Authors: David A Brent; Steven M Brunwasser; Steven D Hollon; V Robin Weersing; Gregory N Clarke; John F Dickerson; William R Beardslee; Tracy R G Gladstone; Giovanna Porta; Frances L Lynch; Satish Iyengar; Judy Garber Journal: JAMA Psychiatry Date: 2015-11 Impact factor: 21.596
Authors: Jeremy G Stewart; Judy C Kim; Erika C Esposito; Joseph Gold; Matthew K Nock; Randy P Auerbach Journal: J Affect Disord Date: 2015-08-19 Impact factor: 4.839
Authors: Lauren Delaparte; Fang-Cheng Yeh; Phil Adams; Ashley Malchow; Madhukar H Trivedi; Maria A Oquendo; Thilo Deckersbach; Todd Ogden; Diego A Pizzagalli; Maurizio Fava; Crystal Cooper; Melvin McInnis; Benji T Kurian; Myrna M Weissman; Patrick J McGrath; Daniel N Klein; Ramin V Parsey; Christine DeLorenzo Journal: J Psychiatr Res Date: 2017-01-24 Impact factor: 4.791
Authors: Nienke R van Alphen; Jeremy G Stewart; Erika C Esposito; Bryan Pridgen; Joseph Gold; Randy P Auerbach Journal: J Clin Psychiatry Date: 2017-05 Impact factor: 4.384